Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.875 USD | -1.39% | +2.94% | +8.02% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.02% | 87.8M | |
+33.06% | 704B | |
+28.59% | 577B | |
-3.80% | 348B | |
+18.29% | 327B | |
+5.47% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.99% | 147B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Kempen Downgrades HOOKIPA Pharma to Neutral From Buy, Adjusts Price Target to $2.60 From $24